信达生物制药（苏州）有限公司 Innovent BiologicsInc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer 2020-12-11 09:02
Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas 2020-12-08 08:00
Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis 2020-11-23 18:34
Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020 2020-11-23 08:00
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Ophthalmology 2020-11-16 08:00
Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day 2020-11-11 08:00
Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020 2020-11-11 08:00
Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020 2020-11-05 08:00
Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group 2020-10-15 08:00
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China 2020-10-09 19:14
Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period 2020-10-07 08:00
Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th 2020-09-28 12:13
TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC) 2020-09-28 10:15
Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020 2020-09-21 08:00
Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020 2020-09-21 08:00
Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 2020-09-14 18:00
Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China 2020-09-03 17:50
Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody 2020-09-01 08:00
Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the European Society of Cardiology Annual Conference 2020-08-31 08:00
Innovent Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Progress 2020-08-27 09:37
1 11 12 13 14 15 17